Clinical Trial

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Study acronym: DELIVER-MS
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2018-05-14; most recent amendment 2025-08-22.
Status change: Recruiting → Active, Not Recruiting 2024-04-30
Status change: Not Yet Recruiting → Recruiting 2019-01-29
Trial Details
NCT Number NCT03535298
Lead Sponsor The Cleveland Clinic
Collaborators: University of Nottingham
Conditions Multiple Sclerosis, Relapsing-Remitting
Enrollment 800 participants
Start Date 2019-01-03
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-28